Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

119 sites for NCT03969004

Skin Squamous Cell Carcinoma

cemiplimab

immunotherapy

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

28 sites for NCT01042379

ERBB2 Amplification, +6 more biomarkers

Invasive Breast Carcinoma

abemaciclib, +26 more drugs

chemotherapy, +4 more types

Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca

1 site for NCT04988074

CDKN2A Overexpression, +1 more biomarker

Head and Neck Squamous Cell Carcinoma

cemiplimab

immunotherapy

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

27 sites for NCT04646005

CDKN2A Overexpression, +1 more biomarker

Cervical Squamous Cell Carcinoma

cemiplimab, +1 more drug

immunotherapy

CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer

2 sites for NCT04916002

ER Negative, +2 more biomarkers

Breast Carcinoma, +2 more conditions

cemiplimab, +1 more drug

immunotherapy

A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

28 sites for NCT04398524

CDKN2A Overexpression, +1 more biomarker

Oropharyngeal Squamous Cell Carcinoma

cemiplimab, +1 more drug

immunotherapy

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

48 sites for NCT04050436

Skin Squamous Cell Carcinoma

cemiplimab, +1 more drug

immunotherapy

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

2 sites for NCT04543071

Pancreatic Adenocarcinoma

BL-8040, +3 more drugs

chemotherapy, +1 more type

A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

53 sites for NCT03669718

CDKN2A Overexpression, +2 more biomarkers

Oropharyngeal Carcinoma, +2 more conditions

cemiplimab, +1 more drug

immunotherapy

REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Adult Male Patients With Metastatic Castration-Resistant Prostate Cancer

1 site for NCT05125016

Prostate Adenocarcinoma

cemiplimab, +1 more drug

immunotherapy

Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma

25 sites for NCT04526899

Cutaneous Melanoma

BNT111, +1 more drug

immunotherapy

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

1 site for NCT04862650

Cutaneous Squamous Cell Carcinoma of the Head and Neck

carboplatin, +2 more drugs

chemotherapy, +1 more type